Efficacy of N-acetylcysteine Versus Placebo as Prophylaxis of Sinusoidal Obstruction Syndrome in Patients Undergoing Hematopoietic Stem Cell Transplantation — ALISON  

Hematopoietic Stem Cell Transplant (HSCT) Clinical Trial

Official title: Prospective, Randomized Study Using N-Acetylcysteine as Prophylaxis of Sinusoidal Obstruction Syndrome in Patients Undergoing Hematopoietic Stem Cell Transplantation

Status Not yet recruiting

Clinical Trial Summary

Sinusoidal obstruction syndrome (SOS) or hepatic veno-occlusive disease (VOD) is a serious complication that occurs, most often occurring in patients undergoing hematopoietic stem cell transplantation (HSCT), especially in its first thirty days. The morbidity and mortality in this syndrome are considerable, since severe SOS is associated with a mortality of more than 90% in the first hundred days of HSCT. Some risk factors are modifiable, especially those related to transplantation, but when non-alterable factors are present, preventive measures are needed that can reduce the incidence and / or severity of SOS.

Clinical Trial Description

This is a single-center, randomized, placebo-controlled study to evaluate the efficacy and safety of N-acetylcysteine as prophylaxis of sinusoidal obstruction syndrome in patients undergoing hematopoietic stem cell transplantation Up to date, no approved medications are available for prophylactic treatment of sinusoidal obstruction syndrome in patients undergoing hematopoietic stem cell transplantation. N-acetylcysteine is a drug that has been long used as a mucolytic. And placebo responses contribute to help assess the appropriateness of randomized clinical trials in determining the size of drug effect. The study will enroll patients undergoing hematopoietic stem cell transplantation to receive sequentially one of two treatment: N-acetylcysteine or Placebo. ;

Related Conditions & MeSH terms

• Hematopoietic Stem Cell Transplant (HSCT)
• Hepatic Veno-Occlusive Disease
• Sinusoidal Obstruction Syndrome (SOS)
• Syndrome

• NCT number: NCT04712435
• Study type: Interventional
• Source: Instituto Brasileiro de Controle do Cancer
• Contact: Jamilla N Cavalcante, MD
• Phone: +55113474-4428
• Email: millacavalcante@hotmail.com
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: April 2021
• Completion date: March 31, 2023